Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales

& Forecast - Worldwide

Renub Researchwww.renub.com

Published: July, 2013Copyright © 2013 Renub Research – All Rights Reserved

From Data to Analysis

Hepatitis C Market Research Report

Hepatitis C Market Overview

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size

of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by

a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low

rates of testing, treatment and the prospect of increasing incidence associated with the

epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-

stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character

of the infection, many people are unaware of having it. As a consequence, the infection is

often diagnosed at a late stage when treatment options are limited. As no effective vaccine

against the Hepatitis C virus (HCV) has been discovered so far the market is driven by

therapeutics. The increase in the prevalence of the disease and the availability of new first-in-

class therapies with better safety and efficacy profiles are expected to drive the growth of the

HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the

market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness

and knowledge about HCV have been identified as a formidable challenge to prevention and

care.

Renub Research study titled “Hepatitis C Drug Market & Forecast, HCV Drugs Clinical Trials,

Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive

assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25

Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7

chapters.

A. Hepatitis C Drugs Market & Forecast (Chapter 2)

B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)

C. Hepatitis C Deals & Acquisitions (Chapter 4)

D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)

E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)

F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)

1. Pegasys

2. Pegintron

3. Incivek

4. Victrelis

© Renub Research Page 2 of 12

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)

1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)

2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)

3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)

4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)

5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)

6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)

7. BI-207127 (Company: Boerhinger Ingelheim)

8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)

9. ABT-267 (Company: Abbott Laboratories)

10. ABT-072/333 (Company: Abbott Laboratories)

11. Alisporivir (Company: Novartis)

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)

1. Mericitabine (RG-7128) (Company: Roche)

2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)

3. GS-9256 (Company: Gilead Sciences)

4. GS-9451 (Company: Gilead Sciences)

5. MK-5172 (Company: Merck)

6. Sovaprevir (ACH-1625) (Company: Achillion)

7. IDX-320 (Company: Idenix)

8. MK-8742 (Company: Merck)

9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)

10. IDX-719 (Company: Idenix)

11. PPI-668 (Company: Presidio Pharmaceuticals)

12. Setrobuvir (ANA-598) (Company: Roche)

13. VX-222 (Company: Vertex Pharmaceuticals)

14. GS-9669 (Company: Gilead Sciences)

15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)

16. BMS-791325 (Company: Bristol-Myers Squibb)

Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

1. Simeprevir (TMC 435)

2. Faldaprevir (BI 201335) (Boerhinger

Ingelheim)

3. Asunaprevir (BMS-650032)

4. Sofosbuvir (PSI-7977 or GS-7977)

5. Daclatasvir (BMS-790052)

6. ABT-450/r (Ritonavir)

7. ABT-072/333

8. Alisporivir

9. Mericitabine (RG-7128)

10. Danoprevir (RG7227)

11. GS-9256

12. Setrobuvir (ANA-598)

13. VX-222

14. GS-9190 (Tegobuvir)

15. BMS-791325

Data Sources

This report is built using data and information sourced from proprietary databases, primary and

secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-

printable sources like search engines, News websites, Government Websites, Trade Journals,

White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,

Industry Portals, Industry Associations and access to more than 500 paid databases.

© Renub Research Page 4 of 12

Table of Contents

1. Executive Summary

2. Hepatitis C Drugs – Market & Forecast

3. Hepatitis C – Approved Drugs Sales & Forecast

3.1 Pegasys Sales and Forecast

3.2 Pegintron Sales and Forecast

3.3 Incivek Sales and Forecast

3.4 Victrelis Sales and Forecast

4. Hepatitis C – Deals & Acquisitions

5. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III)

5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) 5.1.1 Phase I 5.1.2 Phase II 5.1.3 Phase III

5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) 5.2.1 Phase I 5.2.2 Phase II 5.2.3 Phase III

5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) 5.3.1 Phase I 5.3.2 Phase II 5.3.3 Phase III

5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)

© Renub Research Page 5 of 12

5.4.1 Phase II 5.4.2 Phase III

5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) 5.5.1 Phase II 5.5.2 Phase III

5.6 BI-207127 (Company: Boerhinger Ingelheim) 5.6.1 Phase I 5.6.2 Phase II 5.6.3 Phase III

5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb) 5.7.1 Phase I 5.7.2 Phase III

5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories) 5.8.1 Phase I 5.8.2 Phase II 5.8.3 Phase III

5.9 ABT-267 (Company: Abbott Laboratories) 5.9.1 Phase II 5.9.2 Phase III

5.10 ABT-072/333 (Company: Abbott Laboratories) 5.10.1 Phase I 5.10.2 Phase II 5.10.3 Phase III

5.11 Alisporivir (Company: Novartis) 5.11.1 Phase II 5.11.2 Phase III

© Renub Research Page 6 of 12

6. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II)

6.1 Mericitabine (RG-7128) (Company: Roche) 6.1.1 Phase II

6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 6.2.1 Phase I 6.2.2 Phase II

6.3 GS-9256 (Company: Gilead Sciences) 6.3.1 Phase II

6.4 GS-9451 (Company: Gilead Sciences) 6.4.1 Phase II

6.5 MK-5172 (Company: Merck) 6.5.1 Phase I 6.5.2 Phase II

6.6 Sovaprevir (ACH-1625) (Company: Achillion) 6.6.1 Phase II

6.7 IDX-320 (Company: Idenix) 6.7.1 Phase I

6.8 MK-8742 (Company: Merck) 6.8.1 Phase I 6.8.2 Phase II

6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc) 6.9.1 Phase I 6.9.2 Phase II

© Renub Research Page 7 of 12

6.10 IDX-719 (Company: Idenix) 6.10.1 Phase I 6.10.2 Phase II

6.11 PPI-668 (Company: Presidio Pharmaceuticals) 6.11.1 Phase I

6.12 Setrobuvir (ANA-598) (Company: Roche) 6.12.1 Phase I 6.12.2 Phase II

6.13 VX-222 (Company: Vertex Pharmaceuticals) 6.13.1 Phase I 6.13.2 Phase II

6.14 GS-9669 (Company: Gilead Sciences ) 6.14.1 Phase I 6.14.2 Phase II

6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences) 6.15.1 Phase II

6.16 BMS-791325 (Company: Bristol-Myers Squibb) 6.16.1 Phase II

7. Hepatitis C - Pipeline Drugs Sales Forecast

7.1 Simeprevir (TMC 435) Sales Forecast

7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast

7.3 Asunaprevir (BMS-650032) Sales Forecast

7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast

7.5 Daclatasvir (BMS-790052) Sales Forecast

© Renub Research Page 8 of 12

7.6 ABT-450/r (Ritonavir) Sales Forecast

7.7 ABT-072/333 Sales Forecast

7.8 Alisporivir Sales Forecast

7.9 Mericitabine (RG-7128) Sales Forecast

7.10 Danoprevir (RG7227) Sales Forecast

7.11 GS-9256 Sales Forecast

7.12 Setrobuvir (ANA-598) Sales Forecast

7.13 VX-222 Sales Forecast

7.14 GS-9190 (Tegobuvir) Sales Forecast

7.15 BMS-791325 Sales Forecast

© Renub Research Page 9 of 12

Order Form

Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact

Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780

Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to

info@renub.com

Format

Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline

Drugs Sales & Forecast - Worldwide

Single User

(Email from Publisher)

Hard Copy

(Mail Delivery)

CD – Rom

(Mail Delivery)

Global Site License

(Multiple User License)

US$ 1,290 US$ 1,440 US$ 1,390 US$ 2,090

For ordering this report: Three easy ways to place your order:

1) Order online by Credit Card (Visa, MasterCard, etc.):

http://www.renub.com/report/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-

c-pipeline-drugs-sales-forecast---worldwide-118

2) Order by Wire Transfer:

http://www.renub.com/report/wiretransfer.aspx?id=118&pid=1457

To pay by Wire Transfer, please, fill in your contact details in the form below:

© Renub Research Page 10 of 12

Bank Details

Account Name: Renub Research

A/C No.: 109102000023296

Name of Bank: IDBI Bank Ltd.

Swift Code: IBKLINBB010

Bank Address: 4th Floor

Indian Red Cross Building

1 Red Cross Road

Opposite Parliament Street

New Delhi – 110001

India

Contact Information

First Name: Last Name:

Email:

Job Title:

Company:

Address:

City:

Postal/Zip Code:

Country:

Phone:

Mobile:

Fax:

Report Format:

Your message:

© Renub Research Page 11 of 12

3) Order by Check

Please post the check accompanied by this form, to:

Company Address: Renub Research

1st floor,

C-86, Sector -10,

Noida - 201301

Uttar Pradesh

India

Phone: +91-120-421-9822, 424-9780

For free Sample copy report or to view any of our sample work please contact us at

info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us

Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090

LinkedIn: http://www.linkedin.com/company/renub-research

Twitter: http://twitter.com/RenubResearch

© Renub Research Page 12 of 12